The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Parkinson’s Disease: Pathogenesis and Clinical Aspects
Abstract
Metodología: Se empleó el modelo de reserpina como inductor de sintomatología parkinsoniana para poder evaluar los posibles efectos antiparkinsonianos del extracto de Nertera granadensis, así como los efectos de la asociación del extracto con levodopa/carbidopa.Además, se evaluó la posible actividad antioxidante del extracto por medio del ensayo de TBARs.Resultados: En el modelo de reserpina la dosis de 300 mg/kg del extracto etanólico de Nertera granadensis presentó tendencia a revertir la hipocinesia.La asociación de esta dosis con levodopa/carbidopa presentó mejor respuesta comparada con el tratamiento individual del extracto.En la evaluación ex vivo de la actividad antioxidante, no se encontraron diferencias significativas entre los tratamientos, el control, ni el blanco.Conclusiones: El extracto etanólico de Nertera granadensis no presentó efectos antiparkinsonianos significativos.Sin embargo, cuando se asocia con levodopacarbidopa se observa una tendencia a mejorar el desempeño del animal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 783
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
HAMM, R. J., PIKE, B. R., O'DELL, D. M., LYETH, B. G., & JENKINS, L. W. (1994) · Journal of Neurotrauma · doi:10.1089/neu.1994.11.187 · Cited by 641
A rotarod test for evaluation of motor skill learning
Shiotsuki, H., Yoshimi, K., Shimo, Y., Funayama, M., Takamatsu, Y., Ikeda, K., Takahashi, R., Kitazawa, S., & Hattori, N. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.03.026 · Cited by 627
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 568
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 498
Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson's Disease · doi:10.1155/2016/9832839 · Cited by 369
Striatal dopamine mediates hallucination-like perception in mice
Schmack, K., Bosc, M., Ott, T., Sturgill, J. F., & Kepecs, A. (2021) · Science · doi:10.1126/science.abf4740 · Cited by 253
Marsili, L., Rizzo, G., & Colosimo, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00156 · Cited by 243
MAO-inhibitors in Parkinson's Disease
Riederer, P., & Laux, G. (2011) · Experimental Neurobiology · doi:10.5607/en.2011.20.1.1 · Cited by 215
Behavioral tests in rodent models of stroke
Ruan, J., & Yao, Y. (2020) · Brain Hemorrhages · doi:10.1016/j.hest.2020.09.001 · Cited by 204
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders
Tong, J., Rathitharan, G., Meyer, J. H., Furukawa, Y., Ang, L.-C., Boileau, I., Guttman, M., Hornykiewicz, O., & Kish, S. J. (2017) · Brain · doi:10.1093/brain/awx172 · Cited by 201
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199
Waxman, E. A., & Giasson, B. I. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0297-11.2011 · Cited by 194
Monoamine Oxidase B Inhibitors in Parkinson's Disease
Dezsi, L., & Vecsei, L. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170124165222 · Cited by 188
Epidemiology, environmental risk factors and genetics of Parkinson's disease
Delamarre, A., & Meissner, W. G. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.01.001 · Cited by 175
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat
COLPAERT, F. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90110-9 · Cited by 169
Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease
Glajch, K. E., Fleming, S. M., Surmeier, D. J., & Osten, P. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.007 · Cited by 168
Baltacıoğlu, E., Akalın, F. A., Alver, A., Değer, O., & Karabulut, E. (2008) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2008.02.002 · Cited by 142
Vesicular monoamine transporter 2: Role as a novel target for drug development
Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006) · The AAPS Journal · doi:10.1208/aapsj080478 · Cited by 125
Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease
Fernandes, V. S., dos Santos, J. R., Leão, A. H. F. F., Medeiros, A. M., Melo, T. G., Izídio, G. S., Cabral, A., Ribeiro, R. A., Abílio, V. C., Ribeiro, A. M., et al. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.03.008 · Cited by 116
Kurosaki, R., Muramatsu, Y., Kato, H., & Araki, T. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.03.006 · Cited by 80
Skalisz, L. L. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00333-5 · Cited by 76
Behavioral and neurochemical effects induced by reserpine in mice
de Freitas, C. M., Busanello, A., Schaffer, L. F., Peroza, L. R., Krum, B. N., Leal, C. Q., Ceretta, A. P. C., da Rocha, J. B. T., & Fachinetto, R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4118-4 · Cited by 75
Anticancer effect of ursolic acid via mitochondria‑dependent pathways (Review)
Feng, X., & Su, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10171 · Cited by 66
Agonistas dopaminérgicos en la enfermedad de Parkinson
Cánovas, A. A., Luquín, M. R., Ruiz, P., Burguera, J. A., Arillo, V. M. C., Castro, A., Linazasoro, G., del Val, J. L., Vela, L., & Martínez‐Castrillo, J. C. (2011) · Neurología · doi:10.1016/j.nrl.2011.04.012 · Cited by 54
Willard, A. M., Bouchard, R. S., & Gittis, A. H. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.068 · Cited by 53
Furostanol saponins from the rhizomes of Dioscorea japonica and their effects on NGF induction
Kim, K. H., Kim, M. A., Moon, E., Kim, S. Y., Choi, S. Z., Son, M. W., & Lee, K. R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.003 · Cited by 47
DeMaagd, G. A., & Philip, A. (2015) · PubMed · Cited by 40
Anticholinergic burden in Parkinson’s disease inpatients
Lertxundi, U., Isla, A., Solinís, M. Á., Domingo‐Echaburu, S., Hernandez, R., Peral‐Aguirregoitia, J., & Medrano, J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1919-7 · Cited by 37
Thiamine deficiency induces oxidative stress in brain mitochondria of Mus musculus
Sharma, A., Bist, R., & Bubber, P. (2013) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-013-0242-y · Cited by 35
The correlation between Toxoplasma gondii infection and Parkinson’s disease: a case-control study
Oskouei, M. M., Hamidi, F., Talebi, M., Farhoudi, M., Taheraghdam, A., Kazemi, T., Sadeghi-Bazargani, H., & Fallah, E. (2016) · Journal of Parasitic Diseases · doi:10.1007/s12639-014-0595-3 · Cited by 28
Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice
Tadaiesky, M. T., Andreatini, R., & Vital, M. A. B. F. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.004 · Cited by 28
Efecto neuroprotector de fitoquímicos en cultivo de neuronas dopaminérgicas
Sandoval-Ávila, S., Díaz, N. F., Gómez‐Pinedo, U., Canales-Aguirre, A. A., Gutiérrez-Mercado, Y. K., Padilla‐Camberos, E., Márquez-Aguirre, A. L., & Diaz-Martinez, N. E. (2016) · Neurología · doi:10.1016/j.nrl.2016.04.018 · Cited by 24
Galetović, A., Araya, J. E., & Gómez‐Silva, B. (2017) · Revista chilena de nutrición · doi:10.4067/s0717-75182017000400360 · Cited by 17
Behavioral Testing in Mouse Models of Stroke
Balkaya, M., & Endres, M. (2010) · Neuromethods · doi:10.1007/978-1-60761-750-1_13 · Cited by 16
Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Jost, W. H., Friede, M., & Schnitker, J. (2014) · PubMed · Cited by 10
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Olaya, M. D. P., Vergel, N. E., López‐Pérez, J. L., Viña, M. D., & Guerrero, M. F. (2019) · Biomédica · doi:10.7705/biomedica.4299 · Cited by 8
Cited by
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
PINK1/Parkin-mediated mitophagy in neurodegenerative diseases
Li, J., Yang, D., Li, Z., Zhao, M., Wang, D., Sun, Z., Wen, P., Dai, Y., Gou, F., Ji, Y., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101817 · Cited by 383
Lee, D. J., Lozano, C. S., Dallapiazza, R. F., & Lozano, A. M. (2019) · Journal of Neurosurgery · doi:10.3171/2019.4.jns181761 · Cited by 302
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
The Role of miR-128 in Neurodegenerative Diseases
Lanza, M., Cuzzocrea, S., Oddo, S., Esposito, E., & Casili, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076024 · Cited by 27
Metadata
- Venue
- Codon Publications eBooks
- Publisher
- Codon Publications
- Published
- 2018-12-22
- OpenAlex
- W3042654062
- Cited by
- 294
- References
- 40
- FWCI
- 38.67
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.